PMID- 16521187
OWN - NLM
STAT- MEDLINE
DCOM- 20060525
LR  - 20190430
IS  - 1007-9327 (Print)
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Linking)
VI  - 12
IP  - 5
DP  - 2006 Feb 7
TI  - Microproteinuria in patients with inflammatory bowel disease: is it associated 
      with the disease activity or the treatment with 5-aminosalicylic acid?
PG  - 739-46
AB  - AIM: To investigate whether microproteinuria in patients with inflammatory bowel 
      disease (IBD) is associated with the disease activity or the treatment with 
      5-aminosalicylic acid (5-ASA). METHODS: We prospectively studied microproteinuria 
      in 86 consecutive patients with IBD, 61 with ulcerative colitis (UC) and 25 with 
      Crohn's disease (CD), before as well as 2 and 6 months after their inclusion in 
      the study. Forty-six patients received 5-ASA for a period of 28.8 months (range 
      1-168 mo). Microalbuminuria (mALB) and urine levels of the renal tubular proteins 
      beta2-microglobulin (beta2mGLB) and beta-N-acetyl-D-glucosamidase (beta-NAG) as 
      well as the creatinine clearance were determined in a 12-h overnight urine 
      collection. Tumor necrosis factor-alpha (TNF-alpha) serum levels were also 
      measured. RESULTS: A total of 277 measurements (194 in UC patients and 83 in CD 
      patients) were performed. The prevalence of abnormal microproteinuria in UC and 
      CD patients was 12.9% and 6.0% for mALB, 22.7% and 27.7% for beta2mGLB, and 11.3% 
      and 8.4% for beta-NAG, respectively. mALB was not associated with IBD activity. 
      Beta2mGLB and beta-NAG urine levels were correlated to UC activity (UCAI: P<0.01; 
      UCEI: P<0.005). mALB in UC patients and beta-NAG urine levels in CD patients were 
      related to TNF-alpha serum levels. An association was noticed between 
      microproteinuria and smoking habit. Treatment with 5-ASA was not correlated to 
      the severity of microproteinuria or to the changes of creatinine clearance. 
      CONCLUSION: Microproteinuria is mainly associated with UC and its activity but 
      not affected by 5-ASA.
FAU - Poulou, Androniki C
AU  - Poulou AC
AD  - Gastroenterology Department, Red Cross Hospital of Athens, Greece.
FAU - Goumas, Konstantinos E
AU  - Goumas KE
FAU - Dandakis, Dimitrios C
AU  - Dandakis DC
FAU - Tyrmpas, Ioannis
AU  - Tyrmpas I
FAU - Panagiotaki, Maria
AU  - Panagiotaki M
FAU - Georgouli, Androniki
AU  - Georgouli A
FAU - Soutos, Dimitrios C
AU  - Soutos DC
FAU - Archimandritis, Athanasios
AU  - Archimandritis A
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 4Q81I59GXC (Mesalamine)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Colitis, Ulcerative/complications/drug therapy/urine
MH  - Creatinine/blood
MH  - Crohn Disease/complications/drug therapy/urine
MH  - Female
MH  - Humans
MH  - Inflammatory Bowel Diseases/*complications/*drug therapy/urine
MH  - Male
MH  - Mesalamine/*adverse effects
MH  - Middle Aged
MH  - Prospective Studies
MH  - Proteinuria/*etiology
PMC - PMC4066124
EDAT- 2006/03/08 09:00
MHDA- 2006/05/26 09:00
PMCR- 2006/02/07
CRDT- 2006/03/08 09:00
PHST- 2006/03/08 09:00 [pubmed]
PHST- 2006/05/26 09:00 [medline]
PHST- 2006/03/08 09:00 [entrez]
PHST- 2006/02/07 00:00 [pmc-release]
AID - 10.3748/wjg.v12.i5.739 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2006 Feb 7;12(5):739-46. doi: 10.3748/wjg.v12.i5.739.